Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL

Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL

Abstract Chimeric antigen receptor (CAR) T-cell infusion (CTI) therapy has emerged as a breakthrough therapy in relapsed/refractory B-cell non-Hodgkin’s lymphoma (R/R B-NHL), but a substantial number of patients still suffer treatment failure. Data on disease history, subsequent salvage therapies, a...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaoxiang Wang, Meijuan Huang, Lijun Jiang, Xiaoying Zhang, Zhenhao Wang, Qiuxia Yu, Dengju Li, Yang Yang, Xin Yang, Yang Cao
Format: Article
Language:English
Published: Springer 2025-03-01
Series:Cancer Immunology, Immunotherapy
Subjects:
CAR T-cell
B-NHL
Relapsed/Refractory
Salvage therapy
Adverse effects
Online Access:https://doi.org/10.1007/s00262-025-04001-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items